The invention describes peptide ligands specific for human plasma Kallikrein.

The invention describes peptide ligands specific for human plasma Kallikrein.

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

There are provided herein compounds of Formula I, compositions comprising the compounds, and methods for using the compounds. The methods include methods for modulating quorum sensing by Listeria monocytogenes (Lm), methods for reducing the virulence of Lm, methods for inhibiting biofilm formation or growth by Lm on a surface, including food and food processing surfaces, and methods for treating Lm infection in a subject.

There are provided herein compounds of Formula I, compositions comprising the compounds, and methods for using the compounds. The methods include methods for modulating quorum sensing by Listeria monocytogenes (Lm), methods for reducing the virulence of Lm, methods for inhibiting biofilm formation or growth by Lm on a surface, including food and food processing surfaces, and methods for treating Lm infection in a subject.

Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.

Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.

The present invention provides a method for producing a modified compound, including the following steps: (1) a step of cleaving in vitro using a CRISPR/Cas9 system, a target site in a gene cluster involved in the biosynthesis of a compound, (2) a step of connecting using Gibson assembly in vitro the gene cluster cleaved in step (1) and a polynucleotide for modification, and (3) a step of expressing the modified gene cluster obtained in step (2) in a microorganism expression system.

The present invention provides a method for producing a modified compound, including the following steps: (1) a step of cleaving in vitro using a CRISPR/Cas9 system, a target site in a gene cluster involved in the biosynthesis of a compound, (2) a step of connecting using Gibson assembly in vitro the gene cluster cleaved in step (1) and a polynucleotide for modification, and (3) a step of expressing the modified gene cluster obtained in step (2) in a microorganism expression system.